EGFR and neoplasm: In the SW48 (WT-EGFR) xenograft model (Fig. 7a), tumor growth was significantly suppressed in the Ctx-VY, Ctx-Y104D, Ctx-W52D and cetuximab groups compared to the PBS group, and the in vivo antitumor activities of the cetuximab variants were consistent with their binding affinities for EGFR.